Additionally, the 36-month beta value for IPSC is 1.43. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IPSC is 19.93M and currently, short sellers hold a 8.69% ratio of that float. The average trading volume of IPSC on April 26, 2024 was 214.85K shares.
IPSC) stock’s latest price update
The stock price of Century Therapeutics Inc (NASDAQ: IPSC) has jumped by 6.42 compared to previous close of 2.96. Despite this, the company has seen a gain of 5.88% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-23 that PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows:
IPSC’s Market Performance
IPSC’s stock has risen by 5.88% in the past week, with a monthly drop of -20.85% and a quarterly drop of -27.25%. The volatility ratio for the week is 14.13% while the volatility levels for the last 30 days are 11.43% for Century Therapeutics Inc The simple moving average for the past 20 days is -12.07% for IPSC’s stock, with a 6.98% simple moving average for the past 200 days.
Analysts’ Opinion of IPSC
Many brokerage firms have already submitted their reports for IPSC stocks, with JP Morgan repeating the rating for IPSC by listing it as a “Neutral.” The predicted price for IPSC in the upcoming period, according to JP Morgan is $5 based on the research report published on August 28, 2023 of the previous year 2023.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see IPSC reach a price target of $19. The rating they have provided for IPSC stocks is “Buy” according to the report published on December 27th, 2022.
Guggenheim gave a rating of “Buy” to IPSC, setting the target price at $15 in the report published on October 31st of the previous year.
IPSC Trading at -23.20% from the 50-Day Moving Average
After a stumble in the market that brought IPSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.83% of loss for the given period.
Volatility was left at 11.43%, however, over the last 30 days, the volatility rate increased by 14.13%, as shares sank -26.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.89% lower at present.
During the last 5 trading sessions, IPSC rose by +5.88%, which changed the moving average for the period of 200-days by +8.25% in comparison to the 20-day moving average, which settled at $3.53. In addition, Century Therapeutics Inc saw -5.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IPSC starting from Russotti Gregory, who sale 5,000 shares at the price of $3.10 back on Apr 22 ’24. After this action, Russotti Gregory now owns 297,319 shares of Century Therapeutics Inc, valued at $15,490 using the latest closing price.
Farid Adrienne, the Chief Operations Officer of Century Therapeutics Inc, sale 22,831 shares at $5.14 during a trade that took place back on Mar 07 ’24, which means that Farid Adrienne is holding 114,149 shares at $117,342 based on the most recent closing price.
Stock Fundamentals for IPSC
Current profitability levels for the company are sitting at:
- -59.69 for the present operating margin
- -3.44 for the gross margin
The net margin for Century Therapeutics Inc stands at -61.15. The total capital return value is set at -0.39. Equity return is now at value -56.07, with -32.26 for asset returns.
Based on Century Therapeutics Inc (IPSC), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -1.83. The debt to equity ratio resting at 0.26. The interest coverage ratio of the stock is -247.04.
Currently, EBITDA for the company is -112.14 million with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of 91.88. The receivables turnover for the company is 3.36for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.92.
Conclusion
In conclusion, Century Therapeutics Inc (IPSC) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
